To identify the molecular components of the vasoactive intestinal peptide (VIP) binding sites in the liver, 125I-labelled VIP was covalently linked to liver membranes by using the cleavable cross-linker dithiobis(succinimidylpropionate). Purified rat liver plasma membranes were incubated with 125I-VIP, washed and treated with 1 mM-cross-linker. Polyacrylamide-gel electrophoresis of membrane proteins followed by autoradiography revealed a major 125I-VIP-protein complex of M, 51000. A minor Mr 89000 complex was also observed. An identical pattern of protein labelling was obtained using crude membranes from rat liver. Labelling of the M, 51 000 and 89000 species was specific in that it could be abolished by native VIP, but was unaffected by 1 M-glucagon and cholecystokinin octapeptide. Densitometric scanning of autoradiographs indicated that the labelling of the two species was abolished by similar low VIP concentrations (0. I-l00nM). It was also reduced by two VIP agonists, peptide histidine isoleucine amide and secretin, with a potency that is 1/7 and 1/200 that of native VIP, respectively. The guanine nucleotide GTP in the concentration range between 10-7 and 10-3M reduces the labelling of the major M, 51000 protein and that of the minor Mr 89000 protein, but with a slightly higher potency. Assuming one molecule of '251-VIP was bound per molecule of protein, a major M, 48000 protein and a minor Mr 86000 protein were identified as components of the high-affinity VIP binding sites in liver. This contrasts markedly with the pattern of labelling of rat intestinal epithelial membranes, where a M, 73 000 protein was identified as a high-affinity VIP receptor and a Mr 33000 protein as a low-affinity VIP binding site [Laburthe, Breant & Rouyer-Fessard (1984) Eur. J. Biochem. 139,[181][182][183][184][185][186][187], suggesting structural differences between VIP binding sites in rat liver and intestinal epithelium.
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To identify the molecular components of the vasoactive intestinal peptide (VIP) binding sites in the liver, 125I-labelled VIP was covalently linked to liver membranes by using the cleavable cross-linker dithiobis(succinimidylpropionate). Purified rat liver plasma membranes were incubated with 125I-VIP, washed and treated with 1 mM-cross-linker. Polyacrylamide-gel electrophoresis of membrane proteins followed by autoradiography revealed a major 125I-VIP-protein complex of M, 51000. A minor Mr 89000 complex was also observed. An identical pattern of protein labelling was obtained using crude membranes from rat liver. Labelling of the M, 51 000 and 89000 species was specific in that it could be abolished by native VIP, but was unaffected by 1 M-glucagon and cholecystokinin octapeptide. Densitometric scanning of autoradiographs indicated that the labelling of the two species was abolished by similar low VIP concentrations (0. I-l00nM). It was also reduced by two VIP agonists, peptide histidine isoleucine amide and secretin, with a potency that is 1/7 and 1/200 that of native VIP, respectively. The guanine nucleotide GTP in the concentration range between 10-7 and 10-3M reduces the labelling of the major M, 51000 protein and that of the minor Mr 89000 protein, but with a slightly higher potency. Assuming one molecule of '251-VIP was bound per molecule of protein, a major M, 48000 protein and a minor Mr 86000 protein were identified as components of the high-affinity VIP binding sites in liver. This contrasts markedly with the pattern of labelling of rat intestinal epithelial membranes, where a M, 73 000 protein was identified as a high-affinity VIP receptor and a Mr 33000 protein as a low-affinity VIP binding site [Laburthe, Breant & Rouyer-Fessard (1984) Eur. J. Biochem. 139, [181] [182] [183] [184] [185] [186] [187] , suggesting structural differences between VIP binding sites in rat liver and intestinal epithelium.
It is now clearly established that VIP triggers biological responses through specific binding to receptors located at the surface of target cells (Laburthe et al., 1978a) . VIP receptors have been studied functionally in various tissues and often mediate an efficient stimulation of adenylate cyclase by the peptide (Amiranoff & Rosselin, 1982) . This is the case for example in intestinal (Amiranoff et al., 1980a ) and isolated cells promote a dramatic activation of the cyclic AMP production system (Amiranoff et al., 1978; Laburthe et al., 1978a Laburthe et al., ,b, 1979 . In sharp contrast, the great number of high-affinity binding sites identified in liver (Desbuquois et al., 1973; Bataille et al., 1974; Desbuquois, 1974; Laburthe et al., 1978a; Misbin et al., 1982; Gammeltoft et al., 1984) seems to be poorly involved in adenylate cyclase activation. Indeed, VIP induces a very low (Desbuquois et al., 1973; Bataille et al., 1974; Waelbroeck et al., 1981; Guerrero et al., 1981) or even negligible (Amiranoff et al., 1980b ) stimulation of adenylate cyclase activity in liver membranes and is almost ineffective at raising cyclic AMP levels in isolated liver cells (Laburthe et al., 1978a; Feliu et al., 1983) . This corroborates various observations suggesting that VIP does not participate in the physiological control of hepatic glucose metabolism (Kerins & Said, 1973; Wood & Blum, 1982; Souquet et al., 1982; Gammeltoft et al., 1984) . These observations are consistent with the idea that liver VIP binding sites may be involved, at least in part, in non-cyclic-AMP-dependent processes (Amiranoff et al., 1980b) , such as VIP extraction from the portal blood (Misbin et al., 1982; Gammeltoft et al., 1984) and may be different from the VIP receptors efficiently coupled to adenylate cyclase.
The present paper has two objectives. Firstly, by using the cross-linking procedure previously developed to characterize rat intestinal VIP receptors (Laburthe et al., 1984) (Hunter & Greenwood, 1962) at a specific radioactivity of 250Ci/g as described (Laburthe et al., 1977) . It displays the same activity as native VIP in stimulating cyclic AMP accumulation in a cultured cell line (HT-29) which is highly and specifically sensitive to VIP (Laburthe et al., 1978b Neville (1968) and represent step 11 of the method. They were used in most experiments. Crude liver membranes were also prepared by the following method. Liver was homogenized using an electric blender (Waring) for 1 min at high speed. The homogenizing buffer was 0.01 M-triethylamine, pH 7.5, containing 0.25M-sucrose and 5mM-EDTA. The homogenate was centrifuged for 10min at 2600g and the resulting supernatant for 20min at 20000g. The final pellet was washed in 60mM-Hepes buffer, pH7.5, and kept at -80°C until used. The crude membranes were used in the experiment shown in Fig. 5 . Plasma membranes from isolated small intestinal epithelial cells were prepared as described in detail elsewhere (Amiranoffet al., 1978) . Membrane proteins were determined by the method of Bradford (1976) with bovine serum albumin as standard.
Binding of 125I VIP to membranes
Membranes (about 100,ug of protein/ml) were incubated as described (Amiranoff et al., 1980a) for 30min at 30°C with 125I-VIP (0.3 nM) and when necessary other compounds in 2.5 ml of 60mM-Hepes buffer, pH 7.5, containing 2% (w/v) bovine serum albumin and 0.1% (w/v) bacitracin. The reaction was stopped by adding 35 ml of ice-cold 60mM-Hepes buffer, pH 7.5, and membranebound 1251-VIP was obtained by centrifugation for 15 min at 20 000g. The supernatant was withdrawn and the pellet used immediately for subsequent experiments.
Cross-linking conditions and SDS/polyacrylamidegel electrophoresis of membrane proteins Membranes containing bound 1251-VIP were suspended in 1 ml of 60mM-Hepes buffer, pH 7.5, containing 1 mM-DTSP and incubated for 15 min at 4°C as described (Laburthe et al., 1984) . The reaction was stopped by adding 5004u1 of ice-cold 60mM-Hepes buffer, pH7.5, containing 60mM-lysine as a reagent quench (Lomant & Fairbanks, 1976) . The medium was centrifuged for 15min at 20000g and the resulting pellet was suspended by five successive passages through a 25-gauge needle in 60mM-Tris/HCl buffer, pH6.8, containing 10% (v/v) glycerol, 0.001% (w/v) Bromophenol Blue and 3% (w/v) SDS. After heating for 30min at 60°C, the suspension was centrifuged for 20min at 40000g and portions of the supernatant were applied to a 5-20% polyacrylamide slab gel (1.5mm thick) according to the Laemmli (1970) method with a 3% stacking gel. The gels were run, fixed, stained and destained as described (Laburthe et al., 1984) . They were dried and exposed for 3-8 days at -80°C to a Trimax type XM film (3M) with a 3M Trimax intensifying screen. Autoradiographs were scanned at 600nm using a spectrophotometer connected to an Omni-Scribe recorder (Houston Instruments).
Results
When rat liver plasma membranes are incubated with 1 251-VIP at equilibrium, washed free of unbound VIP and treated with 1 mM-DTSP, polyacrylamide-gel electrophoresis of membrane proteins reveals a major Mr 51000 and a minor Mr 89000 125I-VIP-protein complexes (Fig. 1, lane complexes are produced by covalent cross-linking between '25I-VIP and liver membrane proteins: (1) the bands are not detected if DTSP treatment is omitted; (2) the reagent quench lysine when added at 60mM together with 1 mM-DTSP prevents the formation of the two bands; (3) reducing the disulphide bond of DTSP by incubation of DTSPtreated liver membranes with 0.7M-2-mercaptoethanol for 30min at 60°C results in the disappearance of the bands; (4) when albumin is omitted from the incubation medium of membranes, the two labelled complexes are unchanged, ruling out the possibility of the interference of albumin in the labelling pattern. The specificity of labelling of the Mr 51000 and 89000 components is tested by adding native VIP or other peptide hormones together with 125I-VIP (Fig. 1) (Fig. 2) . The fine specificity of the Mr 51 000 and Mr 89000 components is tested with two well-characterized VIP agonists: peptide histidine isoleucine and secretin (Bataille et al., 1980; Laburthe et al., 1983) . Integration of peaks obtained by microdensitometric scanning of autoradiographs indicates that peptide histidine isoleucine and secretin are about 7 times and 200 times less potent than VIP, respectively, in inhibiting the covalent labelling of the two components (Fig. 3) .
The guanine nucleotide GTP was shown previously to regulate the specific binding of 1251-VIP to rat liver plasma membranes (Desbuquois, 1974; Amiranoff et al., 1980b ). We have thus tested its effect on the covalent labelling of the Mr 51000 and Mr 89000 components (Fig. 4) . It appears that GTP in the 10-7-10-3 M concentration range reduces markedly their labelling, with a slightly higher potency for the Mr 89000 component.
The pattern of specific labelling of rat liver membrane proteins by 125I-VIP is not identical with that previously described for rat intestinal epithelial membranes. We have thus compared, within the same experiment and using exactly the same experimental procedure, the two patterns of labelling ( Fig. 5 ). It appears clearly that the apparent Mr values of 1251-VIP-binding site complexes in liver, i.e. 89000 and 51000 (Fig. 5 , lane a), differ consistently from those observed in intestinal epithelium (Fig. 5, lane c) i.e. 76000 for the high-affinity receptor and 36000 for a lowaffinity binding site (Laburthe et al., 1984) . in the two tissues is not due to a difference in the purity of the membrane preparations since crude (Fig. 5 , lane e) and purified (Fig. 5, lane a) Fig. 1 ). This suggests that only a part of the reversible 125I-VIP-binding site complexes has been covalently linked by DTSP treatment. Similar conclusions were drawn for the covalent labelling of intestinal VIP receptors using DTSP (Laburthe et al., 1984) and in general for the cross-linking of peptide hormones to their receptors with hydroxysuccinimide esters (Pilch & Czech, 1979; Rebois et al., 1981; Paglin & Jamieson, 1982; Donner, 1983) .
The major Mr 48000 and the minor Mr 86000 components of liver membranes that are labelled by 125I-VIP display several properties expected for compounds of the specific VIP binding site. Their labelling is inhibited by low native VIP concentrations (see Figs. 2 and 3 ) that compare well with the concentrations needed to saturate VIP receptors in plasma membranes (Bataille et al., 1974; Desbuquois, 1974) or isolated cells (Laburthe et al., 1978a ) from rat liver. Moreover, the ability of secretin and peptide histidine isoleucine to reduce the covalent labelling of the two components is consistent with the low affinity of these peptides for VIP binding sites in liver (Bataille et al., 1980) as well as other tissues (Laburthe et al., 1983) . Taken together these results indicate that the two rat liver membrane proteins that link 1251-VIP may contain the structural domain(s) necessary for recognizing VIP with a high affinity and for discriminating among VIP-related peptides. The attenuation by GTP of their labelling (see Fig. 4 ) suggests moreover that these two components are functionally coupled to a GTP regulatory protein within the liver plasma membranes before DTSP treatment. This is in good agreement with previous reports showing that the guanine nucleotide inhibits 1251-VIP binding to liver membranes by enhancing the rate of dissociation of VIP-binding site complexes (Desbuquois, 1974; Amiranoff et al., 1980b) . (1968) A. Couvineau and M. Laburthe thermore, when binding is also performed in the presence of the potent inhibitor of proteolysis phenylmethanesulphonyl fluoride (results not shown), no modification of the pattern of labelling is observed. These observations contrast markedly with other systems such as, for example, the ,Badrenergic receptors of turkey erythrocytes, where the ratio of photolabelling of the intact receptor and its degradation product are found to be very dependent on the method of tissue preparation and the presence of proteolysis inhibitors (Benovic et al., 1983; Sibley et al., 1984) . The second hypothesis, i.e. the possibility that the minor M, 86000 component results from the covalent cross-linking of a small proportion of the M, 48 000 binding site component to a neighbouring polypeptide within the plasma membrane, may be considered but with several restrictions. Indeed, cross-linking with succinimide esters under the low temperature conditions used in this study leads to very few protein aggregates (Pilch & Czech, 1979) . Furthermore, few pre-existing complexes of major membrane proteins appear to exist at low temperature, and random collisions which can be detected by cross-linking occur only at higher temperatures (Peters & Richards, 1977) . Finally, DTSP has a 1 .2nm span (Lomant & Fairbanks, 1976) and since random collisions are unlikely, it can cross-link only proteins that closely interact within the plasma membrane. In that respect, a good candidate would be a GTP regulatory protein functionally associated with VIP binding sites. This is supported by the ability of GTP to reduce the covalent labelling of the Mr 48000 protein (see Fig. 4 ).
The pattern of specific labelling of rat liver plasma membrane proteins by 1 25I-VIP described here differs markedly from that previously observed in rat intestinal epithelial membranes, where an Mr 73000 component was characterized as a specific high-affinity VIP receptor and an Mr 33000 component identified as a specific lowaffinity binding site (Laburthe et al., 1984) . These striking differences in the patterns of protein labelling are observed within the same experiment using identical conditions for membrane incubation and the cross-linking reaction (see Fig. 5 ). In addition, an identical pattern of labelling is observed for highly purified and crude membranes (see Fig. 5 ), likely indicating that the different purity of the hepatic and intestinal membrane preparations may not account for the discrepancies observed between the two tissues. Thus, our results may reflect biologically significant differences in the structure of VIP binding sites in liver and intestine. Whether this structural difference affects the primary structure and/or the glycosylation of the receptor protein remains to be investigated.
What is clear is that the available data concerning the affinity and structural requirements of VIP binding sites in liver and intestine (Laburthe et al., 1978a; Bataille et al., 1980) did not reveal any functional differences affecting the peptide recognizing domain(s). It may thus be suggested that the differences identified by the cross-linking procedure involve the structural domain of VIP binding sites responsible for the coupling of target proteins within the plasma membrane of intestinal and liver cells. This would be consistent with the markedly different ability of VIP to mobilize the cyclic AMP production system in the two tissues (Laburthe et al., 1978a; Amiranoff et al., 1980b) .
In conclusion, the present paper shows that a major Mr 48000 membrane protein is involved in the specific binding of VIP to liver membranes. It also provides evidence suggesting structural differences between VIP binding sites in liver and intestine. It is, however, clear that ultimate understanding of the nature of these differences will require the purification of individual components of VIP receptor/effector systems. When available, radiolabelled photoaffinity probes for VIP will probably permit a more precise analysis of the structural properties of VIP receptors.
